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The RAS-regulated RAF-MEK1/2-ERK1/2 signalling pathway is de-regulated in a
variety of cancers due to mutations in receptor tyrosine kinases (RTKs), negative
regulators of RAS (such as NF1) and core pathway components themselves (RAS,
BRAF, CRAF, MEK1 or MEK2). This has driven the development of a variety of
pharmaceutical agents to inhibit RAF-MEK1/2-ERK1/2 signalling in cancer and both
RAF and MEK inhibitors are now approved and used in the clinic. There is now much
interest in targeting at the level of ERK1/2 for a variety of reasons. First, since the
pathway is linear from RAF-to-MEK-to-ERK then ERK1/2 are validated as targets per
se. Second, innate resistance to RAF or MEK inhibitors involves relief of negative
feedback and pathway re-activation with all signalling going through ERK1/2, validating
the use of ERK inhibitors with RAF or MEK inhibitors as an up-front combination. Third,
long-term acquired resistance to RAF or MEK inhibitors involves a variety of
mechanisms (KRAS or BRAF amplification, MEK mutation, etc.) which re-instate ERK
activity, validating the use of ERK inhibitors to forestall acquired resistance to RAF or
MEK inhibitors. The first potent highly selective ERK1/2 inhibitors have now been
developed and are entering clinical trials. They have one of three discrete
mechanisms of action – catalytic, ‘dual mechanism’ or covalent – which could have
profound consequences for how cells respond and adapt. In this review we describe
the validation of ERK1/2 as anti-cancer drug targets, consider the mechanism of action
of new ERK1/2 inhibitors and how this may impact on their efficacy, anticipate factors
that will determine how tumour cells respond and adapt to ERK1/2 inhibitors and
consider ERK1/2 inhibitor drug combinations.
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51. Introduction
The RAS-regulated RAF-MEK1/2-ERK1/2 signalling pathway is activated by a range
of extracellular stimuli including growth and differentiation factors, cytokines, hormones
and neuropeptides acting through their cognate receptors (receptor tyrosine kinases,
cytokine receptors, G-protein coupled receptors, etc). This pathway is perhaps best
known for its prominent role in controlling gene expression (Nabet et al., 2015; Yang,
Sharrocks, & Whitmarsh, 2013). Activation of the terminal kinases in the cascade,
ERK1 and ERK2, results in their accumulation in the nucleus where they
phosphorylate various sequence-specific transcription factors to stimulate or repress
gene expression. In this way activation of the ERK1/2 pathway can promote a range
of cellular responses; notably, ERK1/2 signalling promotes cell cycle progression and
cell division but can also drive cell cycle exit, differentiation and irreversible cell
senescence (Meloche & Pouysségur, 2007). These opposing cell fates are made
possible by pathway properties and cellular context; for example, the magnitude and
duration of ERK1/2 activation, which is determined by feedback controls, can dictate
whether a cell proliferates or undergoes cell cycle arrest (Blüthgen & Legewie, 2008)
whilst the consequences of ERK1/2 signalling may also be determined by the
activation of coincident parallel signalling pathways (Mendoza, Er, & Blenis, 2011).
ERK1/2 signalling is by no means confined to the nucleus and ERK1/2 can also target
substrates outside the nucleus to control metabolism and cell survival (Cook, Stuart,
Gilley, & Sale, 2017). Indeed, many aspects of cell physiology are regulated by
ERK1/2 signalling, from the earliest cell lineage choices during development to
decisions to die or survive.
The ERK1/2 signalling pathway has attracted particular attention because it is
deregulated in a wide variety of cancers due to activating mutations in growth factor
receptors and core pathway components, most notably RAS and BRAF (Montagut &
Settleman, 2009). This has driven the development of a variety of pharmaceutical
agents to inhibit RAF-MEK1/2-ERK1/2 signalling in cancer and both RAF and MEK
6inhibitors (RAFi, MEKi) are now approved and used in the clinic (Caunt, Sale, Smith,
& Cook, 2015; Holderfield, Deuker, McCormick, & McMahon, 2014). There is now
much interest in targeting the pathway at the level of the terminal kinases, ERK1 and
ERK2 (ERK1/2). ERK1/2 inhibitors (ERKi) will likely be used in combination to target
tumour cells that are refractory to RAFi or MEKi monotherapy or to overcome or
forestall acquired resistance to RAFi or MEKi. The first potent and highly selective
ERKi have now been developed and are entering clinical trials. In this article we review
the validation of ERK1/2 as anti-cancer drug targets, consider the mechanism of action
of new ERKis and how this may impact on their efficacy, consider ERKi drug
combinations and anticipate factors that will determine how tumour cells respond and
adapt to ERKis.
2. The ERK1/2 signalling pathway.
The core ERK1/2 signalling pathway is a three-tier hierarchical protein kinase cascade
(Figure 1). ERK1/2 exemplify a family of mitogen-activated protein kinases (MAPKs)
which are activated by MAPK Kinases (MAPKKs) which are in turn activated
MAPKKKs (Cargnello & Roux, 2011). Like most protein kinases ERK1/2 are
synthesised in cells as inactivate zymogens. Activation requires phosphorylation of
critical threonine and tyrosine residues in the T-E-Y motif found in the kinase activation
loop; T-E-Y phosphorylation has the effect of rearranging the active site to allow the
correct alignment of ATP and substrate for catalysis. Phosphorylation of the ERK1/2
T-E-Y motif is catalysed by the dual-specificity protein kinases MEK1 or MEK2 (the
MAPKKs), which phosphorylate first the tyrosine and then the threonine in a
processive manner (Aoki, Yamada, Kunida, Yasuda, & Matsuda, 2011). MEK1/2 are
themselves activated by activation loop phosphorylation at conserved serine residues;
this is catalysed by one of several different MAPKKKs including the three RAF protein
kinases (ARAF, BRAF and CRAF). Growth factors activate the ERK1/2 pathway by
first activating the RAS proteins, small monomeric GTPases that are tethered on the
7inner leaflet of the plasma membrane and act as binary switches (Karnoub &
Weinberg, 2008). Binding of growth factors to their receptors results in the recruitment
of guanine nucleotide exchange factors such as Son-of-Sevenless (SOS) to the
plasma membrane where they promote the dissociation of GDP from RAS proteins;
the large molar excess of GTP over GDP in cells ensures that GDP is replaced by GTP
which switches RAS into its active conformation. RAS-GTP then binds to RAF proteins
forming active homo or heterodimers at the plasma membrane, which then
phosphorylate MEK1/2, which in turn activate ERK1/2. Whilst the core pathway is
frequently represented as a simple linear RAF-MEK1/2-ERK1/2 cascade, efficient
signal transmission is dependent on various scaffold proteins, which bring the
component kinases together and also serve to insulate the pathway from cross talk by
other kinases (Good, Zalatan, & Lim, 2011). In addition to scaffolds, signalling fidelity
is made possible by distinct kinase-substrate interactions. For example, ERK1/2 are
proline-directed protein kinases, phosphorylating substrates at S/T-P motifs (Ünal,
Uhlitz, & Blüthgen, 2017); such motifs are found in thousands of proteins that are not
ERK1/2 substrates. Rather, ERK1/2 are directed to phosphorylate bona fide substrates
by the presence of discrete kinase docking domains that are distinct from the S/T-P
phosphoacceptor site (Bardwell, 2006; Cargnello & Roux, 2011).
All reported mammalian cells express two canonical ERK proteins, ERK1 and
ERK2, encoded by distinct genes. ERK1 and ERK2 are 84% identical at the amino
acid level; in the case of the human proteins ERK1 exhibits a 17 amino acid N-terminal
extension and 2 extra amino acids at the C-terminus, making it larger than ERK2.
Gene disruption of erk1 or erk2 in mice has revealed striking phenotypic differences;
erk1-/- mice live and reproduce normally whereas erk2 disruption causes early
embryonic lethality (reviewed in (Buscà, Pouysségur, & Lenormand, 2016). Numerous
studies have sought to define functional differences between ERK1 and ERK2 that
might account for these phenotypic differences. Indeed, any such differences would
be a very important consideration in the design or search for ERK inhibitors. However,
8very few rigorous studies have reported function differences between ERK1 and ERK2
and the emerging consensus is that the two enzymes are functionally redundant, with
differences in mouse knockout phenotype reflecting differences in the abundance of
ERK1 and ERK2. Studies of the mouse erk1 and erk2 proximal promoters suggest
that the difference in expression is in part due to the erk2 promoter being stronger than
the erk1 promoter (Buscà et al., 2015). Finally, mice lacking erk2 live and reproduce
normally when erk1 is ubiquitously expressed from the chicken -actin promoter
(Frémin, Saba-El-Leil, Lévesque, Ang, & Meloche, 2015). These mice exhibited
apparently normal ERK signalling suggesting that the differences in erk1 and erk2
knockout phenotype simply reflect the different contributions each isoform makes to
global ERK activity (Buscà et al., 2016).
MEK1/2-catalysed phosphorylation results in a significant fraction of ERK1/2
entering the nucleus (Lidke et al., 2010) where it can bind to and phosphorylate
transcriptional regulators to control gene transcription; indeed, this is arguably the
classic paradigm for ERK1/2 signalling (Figure 1). ERK1/2 phosphorylate a variety of
sequence-specific transcription factors, including many members of ETS and AP-1
families (O’Donnell, Odrowaz, & Sharrocks, 2012). In many cases these
phosphorylation events promote transcription, through activation of transcriptional
activation domains (TADs) or stabilisation of the relevant transcription factor; in other
cases ERK1/2 phosphorylation represses transcription. As a result the ERK1/2
signaling is a major pathway by which growth factors, cytokines and hormones control
gene expression (Schulze, Lehmann, Jefferies, McMahon, & Downward, 2001).
However, ERK1/2 signalling is not confined to the nucleus and ERK1/2 can also target
substrates outside the nucleus to control metabolism, mitochondrial fission and cell
survival (Balmanno & Cook, 2008; Cook et al., 2017). In this way the ERK1/2 pathway
serves as a master regulator of cell fate. Indeed, ERK1/2 signalling is essential for both
human and mouse embryonic stem cell maintenance and self-renewal and the
9maintenance of ESC genome stability (H. Chen et al., 2015), highlighting a critical role
for ERK1/2 signalling in the earliest cell fate decisions.
Given the role of ERK1/2 signalling in control of cell fates it comes as no
surprise that the pathway is regulated by a complex array of homeostatic negative
feedback controls that fine-tune pathway output. These can broadly be divided into
those that are rapid and direct, operating on the minutes timescale and proceed
through pre-existing components (shown in red in Figure 1), and those that are slower
in onset, depend on new protein synthesis and operate on the hours timescale (shown
in green in Figure 1). Rapid direct feedback mechanisms involve direct inhibitory
phosphorylation of upstream pathway components by ERK1/2 or by ERK1/2-
dependent protein kinases such as RSK. Perhaps the best examples of this are the
ERK1/2 catalysed phosphorylation of CRAF (Dougherty et al., 2005), BRAF (Ritt,
Monson, Specht, & Morrison, 2010) and MEK1 (Eblen et al., 2004), which inhibits
phosphorylation of MEK by the RAF proteins and the phosphorylation of ERK1/2 by
MEK1. The net effect is that ERK1/2 activation propagates a negative feedback loop
that limits its own activation, whereas loss of ERK activity (for example, by treatment
with a RAF or MEK inhibitor) inhibits these feedback loops, thereby activating RAF,
MEK and ERK1/2 and allowing the pathway to adapt to perturbations (Sturm et al.,
2010). Slower feedback loops that confer regulation in the longer term involve the de
novo expression of the dual-specificity phosphatases (DUSPs, also known as MAP
kinase phosphatases or MKPs) and the Sprouty (SPRY) proteins. The DUSPs
inactivate ERK1/2 by dephosphorylating the pT-E-pY motif, providing a temporally
delayed ERK-driven feedback loop that is dependent upon ERK-dependent gene
expression and so ‘reports’ on delivery of the ERK1/2 signal to nuclear targets (Kidger
& Keyse, 2016). In turn, different DUSPs function in different locations allowing spatial
regulation of ERK1/2 output; for example, DUSP5 resides within the nucleus whilst
DUSP6 is found in the cytoplasm. SPRY proteins inhibit ERK signalling at the level of
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RTKs, SOS and by interfering with the RAF catalytic domain (Masoumi-Moghaddam,
Amini, & Morris, 2014).
3. Validation of the ERK1/2 pathway and ERK1/2 as targets in cancer
RAS proteins are mutated at high frequency in human cancer (Bos, 1989). 20-30% of
all human cancers have RAS mutations whilst in some diseases the incidence is
especially high; for example 80-90% of pancreatic ductal adenocarcinomas have
activating mutations in KRAS (Bos, 1989; Karnoub & Weinberg, 2008). These
mutations (typically at codons 12, 13 or 61) render the RAS proteins resistant to the
activity of GTPase-activating proteins (RAS-GAPs) (Martin et al., 1990; Trahey &
McCormick, 1987), which normally terminate RAS signalling by accelerating their
otherwise modest GTPase activity. As a result mutant RAS proteins accumulate in
their active GTP-bound state in the absence of an inductive signal, thereby driving
inappropriate cell proliferation and survival. The discovery of the RAF-MEK-ERK1/2
signalling cascade as the first effector pathway of the RAS proteins (Crews,
Alessandrini, & Erikson, 1992; Howe et al., 1992; Karnoub & Weinberg, 2008; Leevers
& Marshall, 1992; Warne, Vician, & Downward, 1993) immediately prompted interest
from the pharmaceutical sector and quickly led to the discovery of PD98059, an
allosteric inhibitor of MEK1/2, as the first selective pathway inhibitor (Dudley, Pang,
Decker, Bridges, & Saltiel, 1995). Other MEK inhibitors quickly followed (Caunt et al.,
2015) and the availability of these probes quickly led to the recognition that ERK1/2
signalling was a major pathway by which growth factors and RAS drive cell proliferation
(Meloche & Pouysségur, 2007).
Despite these early studies there was some delay before mutant forms of RAF,
MEK or ERK proteins were identified in human cancer. Prior to this a variety of studies
demonstrated that engineered mutant forms of RAF or MEK proteins that were
constitutively active could confer malignant transformation upon tissue culture cells
whereas inactive dominant interfering forms of RAF, MEK or ERK could inhibit RAS-
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dependent transformation. The subsequent demonstration of activating mutations in
BRAF (notably BRAFV600E) in human cancer (Davies et al., 2002), especially in
melanoma but also thyroid, colorectal and more recently hairy cell leukaemia (Tiacci
et al., 2011), was a landmark and provided critical validation that core components of
the ERK1/2 pathway were subject to disease-driving mutations in human cancer. More
recently, activating oncogenic mutations in MEK1 or MEK2 have been described in
melanoma, colorectal cancer and lung cancer (Caunt et al., 2015). Although the
incidence of activating mutations in MEK1 or MEK2 is much lower than that of RAS or
BRAF they may define a subset of lung adenocarcinoma (Arcila et al., 2015) and
provide a critical validation that the RAF-MEK-ERK1/2 pathway is a common cancer-
driving pathway. In addition, emergent mutations in MEK1 or MEK2 are also seen in
tumours that have acquired resistance to BRAF or MEK inhibitors (see below).
Mutations in ERK1 or ERK2 have been reported on the COSMIC database
(http://cancer.sanger.ac.uk/cancergenome/projects/cosmic/). In addition, the
ERK2E322K mutant has been observed at significant frequency in cervical and head and
neck squamous cell carcinomas (Arvind et al., 2005; Lawrence et al., 2014; Ojesina et
al., 2014). This mutant maps to the D-recruitment site or common docking domain and
may exhibit more sustained activity due to defects in DUSP binding. However, it is
apparent that primary disease driving mutations in ERK1 or ERK2 tend to be rarer than
BRAF or even MEK1/2 mutations. Despite this, ERK1/2 remain very well validated
targets themselves for a variety of critical reasons. First, the pathway topology
suggests that signalling proceeds in a linear fashion, namely RAF->MEK1/2->ERK1/2,
and the overwhelming body of evidence supports this contention. ERK1 and ERK2
exhibit >80% sequence identity (Boulton et al., 1991; Buscà et al., 2016) and are the
only known substrates for the dual threonine/tyrosine kinase activity of MEK1/2. For
example, despite the kinase domain ERK5 being highly related to ERK1 and ERK2
(66% sequence identity) and including the same T-E-Y motif within its activation loop,
MEK1 fails to bind to ERK5 (Zhou, Bao, & Dixon, 1995) and fails to activate ERK5 in
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cells (Gilley, March, & Cook, 2009). Indeed, more than 20 years on from their
discovery there is no convincing evidence that MEK1 or MEK2 serve any function other
than to activate ERK1/2, a contention supported by the similar early embryonic lethality
and placental disruption observed in Mek1-/- mice (Giroux et al., 1999) and Erk2-/-
mice (Saba-El-Leil et al., 2003). Much the same can be argued for the RAF proteins. 
Wild type RAF proteins act as RAS-dependent homo- or heterodimers (Freeman, Ritt,
& Morrison, 2013) and can activate their dimer partners in trans whilst the common
BRAFV600E mutant is constitutively active and acts as a monomer; however, in both
cases the only known and universally accepted catalytic function of activated RAF
proteins is to phosphorylate and activate MEK1 and MEK2. The significance of
interactions between RAF proteins and components of other signalling pathways such
as MST2 (Nguyen, Matallanas, Romano, Kholodenko, & Kolch, 2015) or ASK1 (J.
Chen, Fujii, Zhang, Roberts, & Fu, 2001) in cancer is at present unclear. Below
ERK1/2, signalling diverges to hundreds of ERK1/2 substrates and interacting proteins
(Carlson et al., 2011; Courcelles et al., 2013; Kriegsheim et al., 2009; Kubiniok, Lavoie,
Therrien, & Thibault, 2017) that each mediate a subset of the global effects of ERK1/2
signalling. Whilst some of these ERK1/2 substrates are kinases themselves, and
therefore druggable, the effect of targeting these components is limited to a subset of
ERK1/2-dependent events and prcesses and this inevitably limits efficacy. Indeed,
ERK1/2 can be viewed as playing a pivotal distributive role in the pathway, receiving
information from MEK1/2 and then passing it on to hundreds of targets. Thus, the core
RAF-MEK1/2-ERK1/2 pathway can be viewed as a critical bottleneck with inhibition of
ERK1/2 signalling achievable by targeting at the level of RAFs, MEK1/2 or ERK1/2.
Second, innate resistance to clinically approved RAFi or MEKi arises through relief of
negative feedback and ERK1/2 pathway re-activation, validating the use of ERKi with
RAFi or MEKi as an up-front combination (see section 4 below). Third, long-term
acquired resistance to RAFi or MEKi arises through a variety of mechanisms but the
majority of these re-instate ERK1/2 activity validating the use of ERKi to forestall or
13
overcome acquired resistance to RAFi or MEKi (Caunt et al., 2015; A. S. Little, Smith,
& Cook, 2013) (See below).
4. Experiences of RAF and MEK1/2 inhibitors
The first ERK1/2 pathway inhibitor to be clinically approved was the RAFi sorafenib,
which is now used in the treatment of renal cell carcinoma, liver and thyroid cancer,
though its efficacy is thought reflect its significant activity against several RTKs
(Wilhelm et al., 2004). The real breakthrough in ERK1/2 pathway therapeutics came
with the description of the BRAF inhibitor (BRAFi) vemurafenib, which emerged from
a structure-based drug design process and exhibits selectivity for the mutationally
activated forms of BRAF, especially the commonest BRAFV600E mutant, that is
particularly abundant in melanoma (Joseph et al., 2010). Indeed, BRAFV600E-positive
melanoma cells are acutely addicted to their driving oncoprotein and ERK1/2
signalling, such that BRAFis like vemurafenib cause striking inhibition of melanoma
cell proliferation and tumour regression in the clinic (Bollag et al., 2010). This led to the
rapid clinical approval of vemurafenib, and subsequently dabrafenib, both of which
have transformed the treatment of melanoma driven by BRAFV600 mutants (Holderfield
et al., 2014). The high incidence of BRAFV600E mutations in hairy cell leukaemia
suggests that BRAFis may hold promise in this disease also (Tiacci et al., 2015).
However, the striking efficacy of BRAFis is very much limited to BRAFV600-mutant
tumours where the mutant oncoprotein signals as a monomer. In cells with wild type
BRAF, which signals as dimer, binding of BRAFi to one protomer elicits conformational
changes in the dimer partner that result in its activation, driving MEK1/2 and ERK1/2
activation (Hatzivassiliou et al., 2010; Heidorn et al., 2010; Holderfield et al., 2013;
Poulikakos, Zhang, Bollag, Shokat, & Rosen, 2010). This paradoxical RAF activation
requires RAS-dependent RAF dimerization and so is especially profound in cells with
activating mutations in RAS, upstream components (RTKs) or negative regulators of
RAS (NF1). A consequence of this paradoxical RAF activation is the development of
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a range of secondary cutaneous lesions, including papillomas, squamous cell
carcinomas and basal cell carcinomas, all of which limit the efficacy of BRAFi
monotherapy to those cells harbouring BRAFV600 mutants (Holderfield et al., 2014).
The very strong ERK1/2 pathway addiction observed in BRAFV600E melanoma
has meant that MEKis are also effective, with the result that the MEKis trametinib and
cobimetinib are both approved for the treatment of this disease (Caunt et al., 2015).
However, because MEKis are not selective for mutant forms of MEK1/2 (as is the case
for vemurafenib and BRAFV600E) and MEK1 and MEK2 are more rarely mutated in
cancer there is a less profound therapeutic index; as a result the efficacy of MEKi
monotherapy is currently limited by toxicity in normal tissue. This toxicity is mitigated
by combination with BRAFi. Indeed, the recognition that acquired resistance to BRAFi
most frequently involves re-activation of MEK1/2-ERK1/2 signalling quickly led to the
development of BRAFi+MEKi combination therapies (Long et al., 2014) and
cobimetinib is actually approved as part of a BRAFi combination. At least three
different BRAFi+MEKi combinations have been tested and in all cases provide
improved response rates and improved progression free survival and overall survival
with fewer side effects (Queirolo, Picasso, & Spagnolo, 2015). This increased
therapeutic index reflects two unique aspects of the drug combination. First, the drugs
synergise to cause a more profound and durable inhibition of ERK1/2 signalling in
BRAFV600E tumour cells. Second, they are thought to antagonise each other in normal
cells with wild type BRAF; this is because the MEKi counters the paradoxical activation
of ERK1/2 by BRAFi, whilst the paradoxical effects of BRAFi counter ERK1/2 inhibition
by MEKi (Caunt et al., 2015; Holderfield et al., 2014). As a result, the combination has
now become the standard of care in patients with BRAFV600-mutated advanced
melanoma (Holderfield et al., 2014). That said, the experience with BRAFi or MEKi
monotherapy and with BRAFi+MEKi combination therapy is that BRAFV600-mutated
tumours will eventually adapt and acquire resistance (Ahronian et al., 2015). In the
vast majority of cases resistance involves reactivation of the ERK1/2 pathway through
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a variety of different mechanisms (Ahronian et al., 2015; A. S. Little et al., 2013). These
include: amplification of genes encoding mutant RAS proteins or BRAFV600E (Corcoran
et al., 2010; Annette S. Little et al., 2011); the emergence of BRAF splice variants
(Poulikakos et al., 2011); a switch to other RAF isoforms (Villanueva et al., 2010) or
other MEK activators (Johannessen et al., 2010); or the emergence of MEK1/2
mutations (Ahronian et al., 2015; A. S. Little et al., 2013). In these cases there is a
strong rationale for inhibiting at the level of ERK1/2 to forestall or overcome acquired
resistance.
RAFis are not appropriate for use as monotherapy in tumours driven by
mutations in RAS or components upstream of RAS since they promote RAS-
dependent paradoxical activation of RAF and so fail to inhibit, and may even promote
ERK1/2 signalling. This is not an issue with MEKi and inhibition of MEK1/2 remains an
attractive option in RAS-mutant or RAS-dependent tumours (Caunt et al., 2015). Most
clinical trials with MEKi monotherapy in solid tumours have reported clear but modest
response rates. A notable exception is the durable response rate to the MEKi
selumetinib in paediatric neurofibromatosis type 1 (NF1), a disease associated with
loss of RAS-GAP activity and increased activation of wild type RAS (Dombi et al.,
2016). However, it is increasingly apparent that MEKis may require combination with
other agents to fulfil their potential (Caunt et al., 2015) and one important combination
option is dual intra-pathway inhibition through combination with a RAFi or ERKi. One
major limitation of MEKi monotherapy, especially in tumours with mutant RAS, is the
rapid rebound in pathway activation. The ERK1/2-dependent feedback loops that
inhibit MEK1 and the RAF proteins are lost when cells are treated with MEKi with the
result that RAF is reactivated. Since cells typically only utilise a small fraction of their
total MEK1/2 and ERK1/2 this means there is considerable spare MEK1/2 that can be
activated following loss of feedback and which will reinstate or sustain ERK1/2
signalling. This pathway reactivation following loss of feedback (or feedback relief) is
much reduced in cells with BRAFV600E (Friday et al., 2008; Pratilas et al., 2009), which
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signals as a monomer and although still subject to ERK1/2-dependent phosphorylation
(Ritt et al., 2010) appears to be refractory to the inhibitory effects of this ERK1/2-
depndent phosphorylation. However, ERK1/2 rebound is particularly robust in cells
with mutant RAS and therefore limits the durability of pathway inhibition and clinical
response.
In summary, the lessons learnt from BRAFi and MEKi are that durable ERK1/2
pathway shutdown can be achieved in the case of BRAFV600-mutant melanoma and
this can translate into striking clinical responses. However, these responses are
usually short-lived (6-9 months) due to the emergence of acquired resistance which
typically involves reinstating MEK1/2-ERK1/2 signalling. In cells with wild type BRAF,
including those with RAS mutation, MEKi elicits only transient pathway inhibition that
quickly (hours or a few days) rebounds, limiting primary efficacy. In both cases dual
pathway inhibition is indicated, validating ERKi as a rational combination with BRAFi
or MEKi.
5. Small molecule inhibitors of ERK1/2 activity
Protein kinase catalytic domains share a common structure characterised by the
amino- and carboxy-terminal kinase lobes connected by a hinge region (Jianming
Zhang, Yang, & Gray, 2009). The ATP binding pocket is located in a cleft between the
two lobes adjacent to the hinge region, forming a highly druggable cavity which has
been the focus of most kinase inhibitor development (Müller, Chaikuad, Gray, &
Knapp, 2015). However, kinase inhibitors can vary based on the activation status of
the kinase that is preferentially recognised (active or inactive), the mechanism of
binding (reversible or covalent) and the binding site (ATP-binding pocket or allosteric)
(Gross, Rahal, Stransky, Lengauer, & Hoeflich, 2015). Therefore, kinase inhibitors
have been categorised based on their binding mode.
All kinases have a conserved Asp-Phe-Gly (DFG) motif at the N terminus of
the activation loop, which is important for regulating kinase activity. When a kinase is
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active the DFG phenylalanine sits in the hydrophobic pocket between the N- and C-
lobes of the kinase, bringing the DFG aspartate into position to coordinate magnesium
at the active site. Kinase inactivation can occur if the phenylalanine moves out of the
hydrophobic pocket, disrupting the orientation of the aspartate and in some cases
sterically blocking ATP binding (Jianming Zhang et al., 2009). Type I kinase inhibitors
are ATP-competitive compounds that target the ATP-binding pocket when the
activation loop is in an active, “DFG-in”, conformation and mimic the hydrogen bonding
normally formed by the adenine ring of ATP. In contrast, type II kinase inhibitors
recognise, or induce the formation of, an inactive, “DFG-out” conformation of the active
site, thus trapping the kinase in its inactive conformation. Furthermore, this “DFG-out”
conformation exposes an extended, diverse binding pocket consisting of an additional
hydrophobic region directly adjacent to the ATP binding site (Jianming Zhang et al.,
2009). Due to this increased structural diversity it has been postulated that type II
inhibitors may have improved selectivity within the kinome, although the evidence for
this is less clear (Zhao et al., 2014).
Instead of targeting the highly-conserved ATP-binding pocket, kinase inhibitors
can be targeted to other less-conserved allosteric pockets on the target kinase.
Allosteric kinase inhibitors can be classified as either type III inhibitors, which bind in a
pocket adjacent to the ATP-binding site in a mechanism that does not compete with
ATP binding, but may displace it, or type IV inhibitors, which bind to an allosteric site
distinct from the substrate/ATP-binding sites (Wu, Clausen, & Nielsen, 2015). Other
classes of kinase inhibitors include bivalent type V inhibitors that combine elements
from type I–IV inhibitors (Lamba & Ghosh, 2012), and covalent inhibitors which are
able to form irreversible covalent bonds to the kinase active site, typically by reacting
with a nucleophilic cysteine residue (Bauer, 2015).
Within the last 15 years, many small molecule inhibitors of ERK1/2 activity have
been described in the literature and some of these have progressed into clinical trials
(Table 1). Based on their mechanism of action, these ERKis can be classified into four
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distinct groups, which might have significant consequences for how cells respond and
adapt. The majority of the ERKis in development target ERK1/2’s catalytic activity in a
reversible, ATP-competitive manner. These reversible catalytic ERKis can be further
stratified based on their ability to interfere with the activating phosphorylation of
ERK1/2 at its pT-E-pY motif by MEK1/2. Catalytic ERKis solely possess the ability to
inhibit ERK1/2 catalytic activity, whereas “dual mechanism” ERKis are characterised
by their ability to antagonise T-E-Y phosphorylation and thus prevent the formation of
the active conformation of ERK1/2, in addition to inhibiting ERK1/2 catalytic activity.
Additionally, some covalent ERKis are in development; these inhibitors also target the
ERK1/2 active site but are characterised by a prolonged duration of activity due to the
formation of an irreversible covalent bond to the target site. Finally, a range of
approaches have been published attempting to generate allosteric ERKis, which
selectively modulate the ability of ERK1/2 to interact with its binding partners, and thus
enabling more precise regulation of ERK1/2 activity or ERK1/2 biological effects.
(a) Reversible, ATP-competitive ERK1/2 inhibitors
In 2005 Astellas Pharmaceuticals published the first report of a small molecule ERKi.
FR180204 (1 – Table 1) was identified from an in-house chemical library utilising a
high-throughput kinase screen to identify compounds capable of inhibiting ERK1/2-
catalysed phosphorylation of myelin basic protein (MBP) (Ohori et al., 2005).
FR180204 inhibited the in vitro kinase activity of ERK1 and ERK2 with IC50 values of
0.51 µM and 0.33 µM respectively, and was shown to be very selective against ERK1/2
over a group of other kinases including MEK1, with the exception of the structurally-
related MAPK p38α (IC50 10 µM). The co-crystal structure of FR180204 bound to ERK2
revealed that the compound targeted the ATP-binding pocket and this evidence,
together with Lineweaver–Burk analysis of the binding interaction, demonstrated that
FR180204 acted as an ATP-competitive inhibitor of ERK1/2.
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The first nanomolar potency inhibitors of ERK1/2 were a pyrrole-based series
from Vertex Pharmaceuticals which were developed through structure-guided
optimisation (Aronov et al., 2007). This work led to the publication of VTX-11e (5 –
Table 1) a highly selective, type I kinase inhibitor with potent cellular activity against
ERK1/2 (Aronov et al., 2009). Further development of this compound series lead to
the generation of BVD-523 (8 – Table 1) (ulixertinib - Biomed Valley Discoveries), a
reversible, ATP-competitive small-molecule ERK1/2 kinase inhibitor which has
generated promising results in Phase 1 clinical trials (ClinicalTrials.gov Identifier:
NCT01781429) (Germann et al., 2015; B. T. Li et al., 2017).
Following the development of VTX-11e/BVD-523 a range of other reversible,
ATP-competitive ERKi have been published including SCH772984 (6 - Merck) (Morris
et al., 2013), an unnamed tetrahydropyrrolo-diazepenones series (10 - Novartis)
(Bagdanoff, Jain, Han, Poon, et al., 2015; Bagdanoff, Jain, Han, Zhu, et al., 2015),
GDC-0994 (7 – Genentech) (Blake et al., 2016) and an unnamed pyrrolopyrazinone-
based series (16 - AstraZeneca) (Ward et al., 2017). In addition to BVD-523, GDC-
0994 and MK-8353/SCH900353 (a derivative of SCH772984 selected for clinical
development), undisclosed compounds from Eli Lily (LY3214996) and Novartis
(LTT462) have reached phase I clinical trials.
Of these compounds perhaps the most unique is SCH772984, as this
compound was shown to effectively inhibit both ERK1/2 catalytic activity as well as its
phosphorylation by MEK1/2 on its activating pT-E-pY motif (Morris et al., 2013). This
dual mechanism of action demonstrated by SCH772984 clearly contrasted with that of
the previously disclosed ERKi VTX-11e, which in cell-based assays was only able to
inhibit ERK1/2 catalytic activity (measured by the phosphorylation of the ERK1/2
substrate p90RSK), and not the phosphorylation of ERK1/2 itself. Interestingly, when
the effects of SCH772984 treatment were examined over a 36-hour time-course in
A375 cells the pathway rebound, following feedback relief, was able to overcome the
inhibition of ERK1/2 phosphorylation, but not the inhibition of p90RSK phosphorylation,
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which was maintained. This indicates that SCH772984 is more effective at inhibiting
ERK1/2 catalytic activity than the phosphorylation of ERK1/2 by MEK1/2 (Morris et al.,
2013).
SCH772984 is structurally distinct from ERKis 5, 8, 10 and 7, all of which
feature N-acyl β-amino alcohols, being formed of a hinge binding pyridine-indazole
with an extended piperazinephenyl-pyrimidine decoration (Figure 2A). Furthermore,
the dual mechanism of action of SCH772984 suggested that it was able to either bind
inactive ERK1/2 to prevent the phosphorylation and activation of the kinase, or
facilitate dephosphorylation of the active kinase. This mechanism of action and its
unique structure led to the initial theory that SCH772984 displayed properties of both
type I and type II kinase inhibitors (Chaikuad et al., 2014; Morris et al., 2013). If so this
would contrast with other previously reported reversible, ATP-competitive ERK
inhibitors; for example, co-crystal structures have indicated that VTX-11e exclusively
exhibits a type I binding mode (Figure 2B) (Aronov et al., 2009; Chaikuad et al., 2014;
Ohori et al., 2005). The prevalence of type I inhibitors, also seen within the GDC-0994
crystal structure (Fig 2C), is thought to be due to residues in the catalytic domain of
ERK1/2 stabilising the “DFG-in” conformation (Hari, Merritt, & Maly, 2013), thereby
minimising the availability of a “DFG-out” state for type II kinase inhibitor development.
However, detailed structural analysis of SCH772984 bound ERK1 or ERK2
subsequently revealed that the inhibitor did not extend into the type-II binding pocket;
rather the compound induced a novel binding pocket located between the phosphate
binding loop (P-loop) and αC helix making a π-stacking interaction with Y64 (Figure
2A) (Chaikuad et al., 2014). This binding pocket was not present in unphosphorylated,
inactive or phosphorylated, active forms of the kinase. To generate this binding pocket
SCH772984 induces significant structural distortion of the P-loop, where Y36 is flipped
into the ATP pocket above the pyrrolidine ring of SCH772984. This distortion creates
the binding pocket between the P-loop and helix αC, occupied by the pyrimidine ring 
of SCH772984, whilst not affecting other key elements, leaving the DFG motif in an
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“in” conformation (Chaikuad et al., 2014). Multiple kinases can form folded P-loop
conformations and this binding mode correlates with a high degree of selectivity (Müller
et al., 2015).
During the development of SCH772984, researchers at Merck identified initial
hit compounds that were able to bind to both unphosphorylated, inactive and
phosphorylated, active ERK2. Therefore, as well as a conventional, active ERK2
enzyme assay, they developed a coupled ERK2 assay where unphosphorylated ERK2
was pre-incubated with the test compound, then the ability of ERK2 to phosphorylate
a polypeptide substrate was measured following the addition of active MEK1. This
coupled assay encompasses the processes of phosphorylation and activation of ERK2
(and attendant conformational changes) and its ability to phosphorylate a substrate; it
can therefore capture the inhibition of both inactive and activated ERK2 (Deng et al.,
2014; Zhu et al., 2015).
SCH772984 demonstrated high ERK1/2 potency, kinome selectivity and in vivo
efficacy but its high molecular weight and poor ligand efficiency (LE) could present
problems later in development, therefore more drug-like properties were sought
through a novel series. Interestingly, when developing a further compound series with
lower molecular weight and higher LE, researchers at Merck selected a lead
compound which apparently did not retain the ability to inhibit the phosphorylation of
ERK1/2 (Lim et al., 2016). To what extent this choice suggested that the dual
mechanism of action, and specifically the inhibition of T-E-Y phosphorylation, was not
sufficiently valued is unclear. It will be interesting to see what mechanism of action is
ultimately selected as this programme develops.
Recently, when developing a novel pyrrolopyrazinone-based series of
reversible, ATP-competitive ERKi researchers at AstraZeneca also determined the
ability of their compounds to prevent the activation of ERK1/2, in this case by
measuring the levels of phosphorylated ERK1/2 following 2 hour treatment of A375
melanoma cells (Ward et al., 2017). This study revealed that relatively minor changes
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in the structure of the compound, such as switching the chirality of a single methyl
group, could have significant impacts on the ability to inhibit ERK1/2 phosphorylation,
yet retain a similar ability to inhibit ERK1/2 catalytic activity. This indicates that dual-
mechanism and catalytic ERKis are unlikely to be distinct classes, but rather two
extremes of a spectrum of compounds with the ability to prevent ERK1/2
phosphorylation. Structure-activity relationships indicated that the interactions
between the compound and the glycine-rich loop of ERK1/2 might influence the ability
of the compound to inhibit ERK1/2 phosphorylation. However, further studies are
required to identify the key requirements for this binding mode, and the mechanism by
which it prevents ERK1/2 phosphorylation. The lead compound from this study,
compound 35 (16), is a potent, selective ERKi with an in vitro IC50 of <0.3 nM, IC50’s of
12/62 nM for inhibition of p-ERK1/2 and p-p90RSK respectively in A375 cells and
efficacy in tumour xenograft models (Ward et al., 2017). This data suggests that
compound 35 possesses a dual mechanism, however the co-crystal structures
generated for this compound series appear to show a binding mode more similar to
that of the catalytic ERKi VTX-11e than the dual mechanism inhibitor SCH772984.
Therefore, it would be interesting to determine whether this compound is able to induce
robust, durable inhibition of p-ERK in RAS mutant cell lines that are more liable to
feedback relief and pathway rebound.
To generate a dual mechanism profile compounds are likely to induce or
stabilize a conformational state in ERK1/2 that prevents the binding of, or activation
by, MEK, in addition to the ATP-competitive inhibition of ERK1/2 catalytic activity.
However, with the exceptions of VTX-11e, SCH772984 and Compound 35 very little
biological data has been published for most reversible, ATP-competitive ERKis,
therefore it is not possible to determine how many of these inhibitors are solely
catalytic, or possess a dual mechanism of action. However, based on the precedent
of MEKis, we speculate that these two mechanisms of action (dual mechanism versus
purely catalytic) could have significant consequences for how cells respond and adapt
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following compound treatment. In the context of MEKi, compounds that are able to
block the phosphorylation of MEK1/2 by RAF, in addition to inhibiting the catalytic
activity of MEK1/2, have been shown to delay pathway rebound following the collapse
of negative feedback (Hatzivassiliou et al., 2013; Ishii et al., 2013). These MEKi, which
include trametinib, CH5126766 and GDC‑0623, have been termed “feedback buster
MEKis” due to their ability to mitigate some of the consequences of feedback relief and
induce a more durable inhibition of ERK1/2 phosphorylation and cell proliferation in
RAS mutant cell lines (Caunt et al., 2015; Hatzivassiliou et al., 2013; Lito et al., 2014).
Consequently, it is possible to hypothesise that ERKis would also follow this paradigm
with dual mechanism ERKis delaying pathway rebound relative to solely catalytic
inhibitors due to their ability to prevent the phosphorylation and activation of ERK1/2
by MEK1/2. This is to some extent supported by the durable inhibition of p90RSK
phosphorylation observed in the context of negative feedback relief and pathway
rebound following SCH772984 treatment of A375 melanoma cells (Morris et al., 2013).
However, this conclusion is clouded by the fact that A375 cells harbour BRAFV600E,
which is known to exhibit weaker pathway rebound due to feedback relief following
ERK1/2 pathway inhibition, as BRAFV600E is active as a monomer and insensitive to
ERK1/2 inhibitory phosphorylation (Pratilas et al., 2009). Furthermore, no studies to
date have compared the ability of catalytic and dual mechanism ERKi to maintain
durable inhibition of ERK1/2 activity, therefore it is possible that targeting ERK1/2 will
result in prolonged pathway inhibition no matter which mechanism of inhibitor is used.
Catalytic ERKi treatment has been shown to result in the accumulation of p-
ERK (Goetz, Ghandi, Treacy, Wagle, & Garraway, 2014; Morris et al., 2013), and the
phosphorylation of ERK1/2 is known to induce its release from its cytoplasmic anchor
MEK1/2 and enable its subsequent translocation to the nucleus (Plotnikov, Zehorai,
Procaccia, & Seger, 2011). Together this evidence indicates that catalytic ERKi
treatment might induce the nuclear accumulation of phosphorylated, but inhibited
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ERK1/2, whereas dual-mechanism ERKi would prevent the nuclear translocation of
inhibitor bound ERK1/2 (Figure 3). This “primed-state” following catalytic ERKi
treatment may facilitate accelerated nuclear ERK1/2 activity and ERK1/2-dependent
gene expression when pathway rebound overcomes compound efficacy, and could
potentially result in cells recovering more rapidly from treatment with catalytic ERKi
compared to dual-mechanism ERKi.
Alternatively, this nuclear p-ERK1/2 pool induced by catalytic ERKi treatment
could potentially play a role in maintaining the non-catalytic functions of ERK1/2.
Although it is clear that the vast majority of the biological functions of ERK1/2 are
performed via phosphorylation events, evidence for non-catalytic functions of ERK1/2
is accumulating. Direct interaction with ERK2 has been shown to activate a range of
proteins including topoisomerase II (Shapiro et al., 1999), poly(ADP-ribose)
polymerase (PARP) 1 (Cohen-Armon et al., 2007) and DUSP6 (MAPK phosphatase
3, MKP-3) (Camps et al., 1998), in a manner-independent of phosphotransfer activity.
ERK2 is also able to act as a transcriptional repressor of interferon-γ responsive genes 
by directly binding DNA in the promoter regions of these genes and preventing the
binding of the transcription factor C/EBP-β (Hu et al., 2009). Furthermore, ERK1/2 
have been suggested to contribute to regulation of cell-cycle entry in a kinase-
independent manner. Upon nuclear translocation ERK1/2 was able to interact with
lamin A and displace the retinoblastoma (RB) protein, enabling RB phosphorylation by
cyclin-dependent kinases and the release of E2F transcription factors to promote cell
cycle entry (Rodríguez et al., 2010).
Interestingly, with the exception of the activation of its negative feedback
regulator DUSP6, the majority of the known non-catalytic functions of ERK1/2 occur in
the nucleus. This raises the possibility that these processes are regulated by the
nuclear translocation of ERK1/2 for which T-E-Y phosphorylation is a major driver
(Lidke et al., 2010), although not the sole determinant (Caunt & McArdle, 2010).
Therefore, the inability of solely catalytic ERKis to prevent the nuclear accumulation of
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ERK1/2 could be permitting a range of non-catalytic functions of ERK1/2 to continue.
These non-catalytic functions could potentially contribute to reduced efficacy of
catalytic ERKis relative to dual mechanism ERKis or RAF/MEK inhibitors which target
upstream of ERK1/2 and prevent its phosphorylation and nuclear import.
Overall, current evidence would imply that it could be advantageous to develop
dual mechanism inhibitors to target ERK1/2. However, due to the very limited
mechanistic data published on the current ATP-competitive ERKis, the majority of this
evidence relies on knowledge gained from studies of ERK1/2 signalling rather than
ERK1/2 inhibition or knowledge inferred or extrapolated from the mechanism of action
of MEKis. Further studies are required to investigate the different mechanisms of
action of current ERKis in the appropriate signalling and disease context to utilise these
compounds successfully or to design compounds that are more effective.
(b) Covalent ERK inhibitors
In recent years there has been an increased interest in developing targeted covalent
inhibitors for many kinases. This has been driven by the successes of the EGFR/HER2
inhibitors afatinib and neratinib (D. Li et al., 2008; Park et al., 2016) the BTK inhibitor
ibrutinib (Claro et al., 2015) and the EGFRT790M–specific inhibitor osimertinib (Khozin
et al., 2017). Targeted covalent inhibitors act through a two-step mechanism. First,
they bind to their target protein through a reversible interaction, which presents an
electrophilic moiety within the inhibitor in the correct vector towards a nucleophilic
residue within the target protein (typically a cysteine). In the second step this
nucleophilic residue then reacts with the inhibitor to form a covalent interaction, which
can be either reversible or irreversible depending on the nature of the bond formed
(Baillie, 2016; Chaikuad, Koch, Laufer, & Knapp, 2017). This method of inhibition is
proposed to facilitate prolonged inhibition of the target protein and high potency, as the
covalent interaction results in either a very slow off-rate for the inhibitor or a
permanently inhibited target protein, consequently de novo synthesis of the target is
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required to re-establish activity. However, a negative consequence of the inherent
reactivity of covalent inhibitors is that they may exhibit off-target effects by reacting
with cysteines and other reactive residues within the proteome.
An analysis of the kinome, performed by Liu et al., estimated that 200 kinases
possess a cysteine either in or proximal to the ATP binding site, including both ERK1
and ERK2 (Liu et al., 2013). Cys166 of ERK1/2 is a non-catalytic residue located in
the back of the ATP binding pocket, one residue prior to the conserved DFG motif.
The ability of this cysteine residue to form a covalent adduct with an inhibitor was
demonstrated with the resorcyclic acid lactone (RAL) natural product 5Z-7-oxozeaenol
(also known as FR148083, 4 - Table 1) (Ohori et al., 2007). A crystal structure showed
it covalently linked to Cys166 of ERK2 through the cis-enone functionality of the RAL
to form a covalent adduct. However, 5Z-7-oxozeaenol and structurally related RAL
analogues were found to be promiscuous, forming covalent adducts with a number of
kinases that possess a cysteine within their catalytic sites, including MEK1, MKK7,
MKK4 and VEGFR1/2 (Ohori et al., 2007; Schirmer, Kennedy, Murli, Reid, & Santi,
2006)
Building on the discovery that ERK1/2 is susceptible to covalent inhibition,
AstraZeneca utilised an approach to develop covalent inhibitors through repurposing
of existing scaffolds and a structure-guided screen. This identified a number of
compounds that showed good biochemical and cellular activity against ERK2 (Ward
et al., 2015). This compound series binds in the ATP-pocket and forms a covalent
bond with Cys-166 (Figure 2D). The lead, compound 13 (11 – Table 1), showed an in
vitro IC50 of 6.9 nM against ERK2 activity and an IC50 of 53 nM in an A375 cell
proliferation assay. However, it should be noted that IC50 values for covalent inhibitors
are dependent on the timing of the assay as longer incubation times will lead to
increased protein-inhibitor adducts.
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This molecular series has since been used as a template for the synthesis of
chemical probes to manipulate and study ERK1/2 function. Lebraud et al. appended
a trans-cyclooctene (TCO) group to the core pharmacophore of compound 13, allowing
for functionalisation of the inhibitor, and as a result its target protein, through
biorthogonal chemistry (Lebraud, Wright, East, et al., 2016). Such TCO-derivatives
have been used for a number of purposes including in-gel activity based protein
profiling, whereby the selectivity of the inhibitor can be assessed by reacting the TCO
tag with a fluorophore, and identification of protein-inhibitor adducts using an SDS
PAGE gel (Lebraud, Wright, East, et al., 2016). Further uses of these TCO-
derivatives include guiding an E3 ubiquitin ligase to accelerate the degradation of
ERK1/2 in a proteolysis targeting chimera (PROTAC) approach (Lebraud, Wright,
Johnson, & Heightman, 2016), and imaging of endogenous inhibitor-bound ERK1/2
using confocal microscopy to track localisation of ERK1/2 within cells (Sipthorp et al.,
2017).
Although covalent inhibitors have the potential to be an effective tool to inhibit
ERK1/2 signalling they have yet to achieve any success in the clinic. The only Phase
I clinical trial to date utilising a covalent ERKi was initiated by Celgene in 2014,
however, this study was terminated because “the maximum tolerated dose (MTD) did
not offer a sufficiently encouraging profile to proceed with the additional dosing
schedule or the cohort expansion phase” (NCT02313012). This possibly reflects the
reactivity of covalent inhibitors and their propensity for off-target effects. As such
further studies are required to develop selective, covalent ERK1/2 inhibitors with
efficacy in the clinic.
(c) Allosteric ERK1/2 inhibitors
In addition to targeting the catalytic site of ERK1/2, efforts have been made to develop
allosteric ERKis, which bind at sites distinct from the catalytic cleft and interfere with
the ability of ERK1/2 to interact with its binding partners. The disruption of protein-
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protein interactions (PPIs) is considered challenging due to the extensive and
sometimes relatively featureless interfaces involved; however the identification of
interaction hot-spots led to the appreciation that blocking the entire interface is not
required to successfully block PPIs (Whitty & Kumaravel, 2006; Yap, Worlikar,
MacKerell, Shapiro, & Fletcher, 2011). This knowledge, coupled with the diverse
structural nature of allosteric binding pockets makes them promising alternatives to
catalytic kinase inhibitors, with potentially high selectivity and the ability to target
tumours which evolve drug-resistance to conventional catalytic kinase inhibitors (Wu
et al., 2015). Furthermore, ERK1/2 are known to have more than 200 substrates and/or
binding partners and contain two major substrate binding sites, the D-recruitment site
(DRS) and the F-recruitment site (FRS); therefore allosteric inhibitors targeted at one
site may enable modulation of the activity of select ERK1/2 substrates (Yap et al.,
2011).
Shapiro and colleagues reported the first putative small molecule, allosteric
ERKi in 2005 (Hancock et al., 2005). This study utilised computer-aided drug design
to perform an in silico screen for compounds which could target a polar cleft between
the acidic common docking (CD) domain and the ED (Glu-Asp) site of the DRS
observed in the crystal structure of unphosphorylated ERK2. From this screen, 80
potential compounds were selected for testing in biological assays, of which several
were able to inhibit ERK1/2-mediated phosphorylation of the D-domain containing
substrates p90RSK and the transcription factor ELK-1. Furthermore, these compounds
inhibited the proliferation of several cancer cell lines. Lead compound 76 (2 – Table 1)
was shown to interact with ERK1/2 in a manner which did not compromise its
phosphorylation or catalytic activity, supporting its predicted binding mode to the DRS
of ERK1/2 (Hancock et al., 2005). Structure-activity relationship (SAR) studies have
investigated the crucial structural features of compound 76 responsible for its biological
activity and further optimised the potency of this compound series (Q. Li et al., 2009;
Boston et al., 2011; Jung et al., 2013). However, it should be noted that these allosteric
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inhibitors possess functionality that would not be desirable for a medicinal chemistry
program. For example, compound 76 has a core structure of an ene-rhodanine, a
reported pan-assay interference compound (PAINS) motif (Baell & Walters, 2014).
Therefore, when using these compounds suitable controls should be put in place to
ensure that any effects seen are due to the desired on-target mechanism of action
(MOA).
The activation of ERK1/2 by phosphorylation has been suggested to induce
subtle structural changes in the region of its DRS (Hoofnagle, Resing, Goldsmith, &
Ahn, 2001), therefore Shapiro and colleagues performed a second in silico screen to
identify compounds which potentially bind the DRS of phosphorylated ERK2 (F. Chen
et al., 2006). The majority of compounds identified by this second screen were the
same as those identified by the initial screen. However, the screen also revealed a
group of novel compounds (3 – Table 1), which were able to bind ERK1/2 and inhibit
the phosphorylation of p90RSK and ELK-1 (F. Chen et al., 2006). Finally, Shapiro and
colleagues have also applied this in silico screening approach to identify compounds
which potentially bind to the FRS of unphosphorylated ERK2 (Samadani et al., 2015).
The FRS is thought to be responsible for the interaction of ERK1/2 with a distinct set
of substrates compared to the DRS, although some substrates such as ELK-1 have
been shown to utilise both domains to bind to ERK1/2 (Burkhard, Chen, & Shapiro,
2011). The ERK2-FRS in silico screen identified a diverse range of compounds which
inhibited EGF-stimulated phosphorylation of ELK-1, but not p90RSK, in HeLa cells,
supporting a MOA which inhibits FRS-mediated ERK2 interactions. The binding of
these compounds was modelled in silico, enabling the utilisation of structural
information and site identification by ligand competitive saturation (SILCS) simulations
to optimise the compound series. The resulting lead compound, SF-3-030 (12 – Table
1), was shown to inhibit ELK-1 phosphorylation, the expression of ERK1/2-dependent
immediate early genes and proliferation in BRAF-mutant melanoma cell lines
(Samadani et al., 2015). However, SF-3-030 also contains moieties that may be widely
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reactive to protein residues, such as its vinyl sulfone, which could undergo undesired
covalent linkages to proteins. Again, suitable controls will need to be in place to ensure
that the phenotype observed is due to prevention of ERK1/2 FRS-mediated
interactions and inhibition of downstream signalling. For example, these agents should
be ineffective in cells that are not addicted to ERK1/2 signalling.
In addition to the DRS and FRS, the mutagenesis of ERK2 has identified a
range of other residues that could be important for its interactions with substrate or
regulatory proteins (Jialin Zhang, Zhou, Zheng, & Zhang, 2003). These include a
unique region within the MAP kinase insert which appears to specifically regulate
interactions with MEK1/2 (Robinson, Whitehurst, Raman, & Cobb, 2002) and a
leucine-rich dimerisation interface (Khokhlatchev et al., 1998; Wilsbacher et al., 2006).
Therefore, if further ERK1/2 binding domains are characterised, this could facilitate the
development of additional allosteric ERK1/2 inhibitors. ERK1/2 activation by
phosphorylation is known to induce dimerisation, as well as substrate binding
(Khokhlatchev et al., 1998). Recent molecular biology studies have shown that ERK1/2
dimers and scaffolds are required for the optimal activation of cytoplasmic, but not
nuclear, substrates and that preventing ERK1/2 dimerisation is able to inhibit tumour
cell proliferation and tumour development (Casar, Pinto, & Crespo, 2008). This
evidence validated ERK1/2 dimerisation as a potential target for the development of
novel ERK inhibitors, therefore Herrero and colleagues developed a native gel
electrophoresis approach to screen for inhibitors of ERK1/2 dimerisation (Herrero et
al., 2015). This screen identified DEL-22379 (13 – Table 1) as a small molecule
capable of inhibiting ERK1/2 dimerisation, without affecting ERK1/2 phosphorylation
or catalytic activity. DEL-22379 inhibited the phosphorylation of ERK1/2 cytoplasmic
substrates and the proliferation of tumour cell lines and xenografts harbouring RAS-
ERK1/2 pathway oncogenes. Furthermore, DEL-22379 demonstrated efficacy against
BRAF or MEK inhibitor resistant cells, and hypothetically could potentially retain
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efficacy in cases where cell lines evolve resistance to ATP-competitive ERK1/2 kinase
inhibitors (Herrero et al., 2015).
Together these academic studies have revealed that it is possible to inhibit
different ERK1/2 binding interactions, advocating the continued development of
allosteric approaches to inhibit ERK1/2. Such efforts have identified a range of
compounds that inhibit different ERK1/2-substrate interactions, which could be of use
for biochemical studies of ERK1/2 function, as well as having the potential to be
developed into therapeutic agents. However, many of the molecules identified to date
possess moieties that have been reported as PAINS, such as electrophilic Michael
acceptors that predispose them to non-specific protein interactions. Consequently,
these compounds may induce many off-target effects, complicating their use as tool
compounds without proper controls in place.
6. Prospects for ERK1/2 inhibitors as monotherapy and in combination
Work described in the previous sections clearly validates the use of ERKis as a new
weapon to treat tumours that are driven by mutational activation of the ERK1/2
pathway. Since mutations in ERK1/2 are quite rare in human cancer and, as far as is
known, ERKis do not discriminate between mutationally activated or wild type ERK1/2
it must be anticipated that ERKi monotherapy will face the same challenges as MEKi
monotherapy; the most obvious being a narrow therapeutic index arising from the
inhibition of ERK1/2 signalling in both normal and tumour cells and resultant toxicity.
Indeed, reports from the Phase I dose escalation and expansion study of BVD-
523/ulixertinib reported similar adverse events as those previously seen with MEKi
including rash, diarrhoea, fatigue and nausea (B. T. Li et al., 2017). However, this trial
also revealed some encouraging results; the 9 patients (of 83) who exhibited a partial
response were found to have tumours with mutations in BRAF (V600E, G469A or
L485W) or NRAS, suggesting that clinical activity was related to pathway de-regulation
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and ERK1/2 addiction. Indeed, the most obvious use for ERKi monotherapy is in the
treatment of patients with BRAF-mutant cancer that has initially responded well to
BRAFi (and is therefore addicted to ERK1/2 signalling), but has then developed
resistance through ‘on-pathway’ mechanisms that reinstate ERK1/2 signalling.
Beyond monotherapy there is clearly a strong case for developing ERKi combinations
with other ERK1/2 pathway inhibitors. As with MEKis, ERKis would be expected to
antagonise the activation of ERK1/2 observed in normal cells arising from paradoxical
RAF activation. Thus, BRAFi+ERKi combinations would be expected to have superior
efficacy and be better tolerated than BRAFi alone in BRAFV600 melanoma as is the
case for BRAFi+MEKi. As outlined above, there is also a strong case for testing ERKi
in combination with either RAFi or MEKi to mitigate ERK1/2 reactivation arising from
feedback relief in tumour cells with RAS mutations. Beyond the ERK1/2 pathway, ERKi
should certainly be tested with other emerging targeted agents (inhibitors of MTOR,
PI3K or PKB/Akt) as well as with appropriate ‘standard-of-care’ cytotoxic
chemotherapy in tumours with RAS mutations. A further attractive option will be to
combine ERKi with inhibitors of cell survival pathways. In common with MEKi, ERKi
typically exert a cytostatic effect and this is most likely due to the buffering effect of
pro-survival BCL2 proteins (BCL2, BCL-XL, MCL1) (Cook et al., 2017). A series of ‘BH3
mimetics’ that bind and inhibit the activity of select pro-survival proteins have already
been developed and are undergoing clinical evaluation and there is already precedent
that RAFi or MEKi can synergise with these agents to promote cell death in ERK-
addicted tumour cells (Corcoran et al., 2013; Cragg et al., 2008; Sale & Cook, 2013).
Finally, ERKi (with MEKi or BRAFi) will undoubtedly be tested in combination with
immunotherapy; indeed pre-clinical models have supported the testing of
BRAFi+MEKi+immunotherapy in BRAFV600E melanoma models (Hu-Lieskovan et al.,
2015). The challenge with all these combinations will be to balance any synergy in the
tumour cell with the increased toxicity arising from activity in non-tumour tissue.
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Dosing, scheduling and stratification biomarkers for identifying responsive patient
populations will all play a part.
Whether ERKis are used alone or in combination, experience with BRAFi or
MEKi has taught us to anticipate the emergence of ERKi resistance in tumours that
show initial favourable responses; indeed, in vitro mutagenesis studies have already
anticipated potential resistance mechanisms (Goetz et al., 2014). Goetz et al subjected
the ERK1 and ERK2 cDNAs to random mutagenesis in E. coli, expressed them in
BRAFV600E-positive A375 melanoma cells and selected them in the presence of the
ERKi inhibitor VTX-11e, the MEKi trametinib or a MEKi+RAFi combination (trametinib
+ dabrafenib) (Goetz et al., 2014). ERK1/2 mutations arising from selection in the ERKi
VTX-11e were also cross-resistant to SCH772984 and were found to cluster within the
ATP/drug binding pocket. Indeed, subsequent experiments demonstrated that these
mutant ERK1/2 proteins were refractory to ERKi, strongly suggesting that they are ‘on
target’ resistance alleles that act by interfering with drug binding. In contrast, the
ERK1/2 mutants arising from selection in RAFi/MEKi were distributed more widely
throughout the ERK proteins; however, some mutations clustered in the αC helix and 
the common docking domain. Indeed, the ERK2E322K mutation that is observed as a
primary mutation in squamous cell carcinomas and sustains active ERK1/2 by
preventing DUSP binding was amongst these mutants. Whilst these mutants were
generated ‘artificially’ rather than in cells they are clearly homing in on well understood
vulnerabilities in protein kinases so it is highly likely that functionally similar mutations
will arise in human tumours undergoing RAFi, MEKi or ERKi treatment and mitigation
should be considered. In this context, it is notable that some of the ERK1/2 mutants
arising during RAFi/MEKi selection were still sensitive to ERKi providing further




The clinical precedent of BRAFis and MEKis, both alone and in combination, together
with pathway topology and the pivotal distributive role of ERK1/2 within the pathway
provide strong rationale for developing inhibitors of ERK1/2. This has fuelled the
development of a variety of novel, drug-like molecules and chemical probes that target
ERK1/2. To date, attempts to develop allosteric inhibitors of ERK1/2 (dimerization
inhibitors or substrate binding blockers) have not led to any drug-like molecules.
Indeed, the utility of some of these probes as research tools is far from clear as many
possess moieties such as electrophilic Michael acceptors that predispose to non-
specific protein interactions. A critical control for these compounds will be to test their
selectivity in biological systems by expressing non-drug binding mutants of ERK1/2;
these should rescue biological effects if those effects are due to ‘on-target’ ERK1/2
inhibition. To date only two covalent ERKis have been described but these provide
strong proof-of-concept that this approach may work, whilst the successful
development of covalent inhibitors of BTK, EGFR/HER2 and EGFRT790M are
compelling examples of what can be achieved. The furthest advanced ERKis are a
variety of ‘traditional’ reversible ATP-competitive ERK1/2 inhibitors that are now
undergoing various stages of clinical evaluation. These include molecules which are
purely inhibitors of ERK1/2 catalytic activity and those which additionally are able to
block MEK1/2-catalysed ERK1/2 T-E-Y phosphorylation. Intuitively, this latter ‘dual-
mechanism’ seems more attractive as it may limit the extent of ERK1/2 reactivation
following feedback relief. However, the biological and clinical importance of this dual
mechanism remains to be seen and it is notable that the lead compound selected from
the SCH772984 programme did not retain the ability to inhibit the phosphorylation of
ERK1/2 (Lim et al., 2016). Finally, since the ATP-competitive ERKis do not have the
exquisite selectivity, specificity even, of the allosteric MEKis, they are each likely to
exhibit their own unique profile of ‘off target’ activity against different subsets of
kinases; this unique polypharmacology may enhance efficacy or may enhance toxicity
and we await the results of ongoing trials with interest.
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Figure Legends
Figure 1. The RAF-MEK1/2-ERK1/2 cascade.
A simplified representation of the RAS-regulated RAF–MEK1/2–ERK1/2 signalling
cascade. Activated growth factor receptors recruit the guanine nucleotide exchange
factor SOS (son of sevenless), to induce the release of GDP from RAS. This enables
the binding of GTP, activating RAS. RAS-GTP promotes the dimerisation and
activation of the RAF kinases (ARAF, BRAF and CRAF), which phosphorylate and
activate MEK1 and MEK2 (MEK1/2), which in turn phosphorylate and activate the
terminal kinases ERK1 and ERK2 (ERK1/2). Phosphorylation of ERK1/2 promotes
their nuclear translocation allowing the phosphorylation and activation of transcription
factors, including the ETS family, to regulate gene expression and modulate many
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critical aspects of cell physiology. For example, ERK1/2 signalling drives the
expression of many transcription factors (e.g., FOS, FRA1, EGR1) which in turn control
the expression of genes involved in feedback regulation of the pathway (see below),
control of cell cycle progression (CCND1, p21CIP1, p16INK4A) and control of cell
survival (MCL1, BCL2, BCL-XL). ERK1/2 also target a large number of cytoplasmic
substrates enabling the pathway to regulate further processes including cell migration
and apoptosis. The ERK1/2 pathway is regulated by an extensive range of negative
feedback systems, allowing the fine-tuning of magnitude, duration and localisation of
pathway output. These negative feedback controls can be divided into two major
mechanisms. The first is the rapid ERK1/2-catalysed inhibitory phosphorylation of
upstream pathway components such as BRAF, CRAF, MEK1, SOS and some receptor
tyrosine kinases (RTKs) (shown in red). The second mechanism requires the de novo
expression of negative regulators including MAP Kinase Phosphatases (MKPs or
DUSPs) and Sprouty proteins (shown in green). This delayed, long term mechanism
acts to dampen pathway activity following induction of the required pathway output.
The ERK1/2 pathway is frequently de-regulated in cancer due to mutations in
components such as BRAF, RAS, NF1, MEK or certain RTKs (indicated by yellow
stars).
Figure 2. Crystal structures of a number of ERK1/2 inhibitors bound to ERK2.
(A) SCH772984 binds to the hinge region of the kinase, with the kinase adopting a
“DFG-in” conformation. SCH772984 also binds within a new pocket between the αC
helix and the P-loop of the kinase, revealed when Y36 flips into the ATP pocket, within
which the terminal pyrimidine of SCH772984 makes a π-stacking interaction with Y64.
(B-C) VTX-11e and GDC-0994 both bind to ERK2 in a manner consistent with Type I
inhibitors, with the kinase in a “DFG-in” conformation and with Y36 outside of the ATP
pocket. (D) Compound 10 binds to the hinge region of ERK2, presenting the
electrophilic acrylamide towards C166, which subsequently reacts to form a covalent
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bond, as shown in crystal structure. Main structure of the protein is shown as a ribbon
in orange with certain areas highlighted for clarity, hinge – dark blue, P-loop – dark
green, αC helix – violet, DFG motif – red, Y64 – purple, Y36 – light blue. Inhibitors are
shown with carbon – light green, nitrogen – blue, oxygen – red, chlorine – dark green,
fluorine – cyan, sulphur – yellow. Structures were taken from the PDB under the
following accession codes; SCH772984 – 4QTA, VTX-11e – 4QTE, GDC-0994 – 5K4I,
compound 10 – 4ZZO. The PDB structures were modified by removing all solvents
and ions for clarity, before colour coding the protein and inhibitors as described above.
Images were produced using Maestro 11.1 Schrödinger release 2017-4.
Figure 3. Catalytic and dual mechanism ERK1/2 inhibitors could differentially
regulate the localisation of ERK1/2.
A purely catalytic ERK1/2 inhibitor should allow the nuclear accumulation of ERK1/2
since it will not prevent activating phosphorylation by MEK1/2. Indeed, in cells with wild
type BRAF a catalytic ERK1/2 inhibitor should induce feedback relief, resulting in
increased RAF-dependent activation of MEK, leading to further accumulation of p-
ERK1/2. The phosphorylation of ERK1/2 promotes its nuclear translocation, therefore
a pool of inhibitor-bound ERK1/2 might accumulate in the nucleus. In contrast, dual
mechanism ERK1/2 inhibitors could disrupt the phosphorylation of ERK1/2, and
reduce the nuclear translocation ERK1/2, resulting in a pool of inhibitor-bound ERK1/2
in the cytoplasm.
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Lim et al., 2016;
Morris et al., 2013;









(Blake et al., 2014,
2016; Ren et al.,























CC-90003 9 N/A 2014 Celgene Covalent Notavailable Phase I














Pre-clinical (Bagdanoff et al.,2015a, 2015b)
AZ13767370
(Compound 13) 11 2015 AstraZeneca Covalent 6.9


















Research tool (Herrero et al., 2015)


























Pre-clinical (Ward et al., 2017)
KO-947 17 N/A 2017 Kura Oncology Not available 10 Phase I





The year reported is based on the earliest publication or clinical trial start date of the compound in question.
*No evidence these compounds are able to inhibit the phosphorylation of ERK and therefore possess a “dual mechanism”, however limited in vivo biological data has been published for these compounds.
‡ Due to their nature as covalent inhibitors, IC50 values cannot be compared between assays, as the time of incubation will affect the relative potency of the compounds.
† Structure of LY3214996 is taken from Selleck Chem, which corresponds to a structure disclosed within an Eli Lily patent, however, to our knowledge the structure has not been disclosed in any primary literature.



